| Identification | Back Directory | [Name]
Rilotumumab | [CAS]
872514-65-3 | [Synonyms]
Rilotumumab
Rilotumumab (anti-HGF)
Research Grade Rilotumumab(DHD03702) |
| Hazard Information | Back Directory | [Description]
Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation. | [Uses]
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2]. | [Clinical Use]
A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients. | [in vivo]
Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo[2]. | Animal Model: | 6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells[2] | | Dosage: | 1.5 mg/kg | | Administration: | Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days | | Result: | Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001). |
| [References]
[1] Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. DOI:10.1158/1078-0432.CCR-12-2605
[2] Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87. DOI:10.1038/onc.2014.448 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|